The store will not work correctly when cookies are disabled.
3-(4-(2-hydroxyethyl)phenylamino)-1-(4-propoxyphenyl)pyrrolidine-2,5-dione
ID: ALA3736205
Cas Number: 342406-05-7
PubChem CID: 2936770
Max Phase: Preclinical
Molecular Formula: C21H24N2O4
Molecular Weight: 368.43
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: CCCOc1ccc(N2C(=O)CC(Nc3ccc(CCO)cc3)C2=O)cc1
Standard InChI: InChI=1S/C21H24N2O4/c1-2-13-27-18-9-7-17(8-10-18)23-20(25)14-19(21(23)26)22-16-5-3-15(4-6-16)11-12-24/h3-10,19,22,24H,2,11-14H2,1H3
Standard InChI Key: AJDMSARFYPOETQ-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 29 0 0 0 0 0 0 0 0999 V2000
1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5973 -1.5031 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5951 -3.0039 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6331 -3.6060 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.6003 1.4977 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.8990 0.7455 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.2526 1.3618 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2524 0.2436 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-5.4979 -1.0529 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0317 -0.7359 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.9821 -2.1508 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-5.4992 2.5362 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-7.7454 0.3952 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-8.4584 1.7093 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.9579 1.7482 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-10.7413 0.4691 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-10.0252 -0.8490 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-8.5257 -0.8879 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-12.2417 0.5049 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-13.0237 -0.7761 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-14.5241 -0.7403 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-15.1494 -1.7645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
1 7 1 0
7 8 1 0
8 9 1 0
4 10 1 0
10 11 1 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
15 11 1 0
14 16 2 0
12 17 2 0
13 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 18 1 0
21 24 1 0
24 25 1 0
25 26 1 0
26 27 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 368.43 | Molecular Weight (Monoisotopic): 368.1736 | AlogP: 2.75 | #Rotatable Bonds: 8 |
Polar Surface Area: 78.87 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 10.78 | CX Basic pKa: 2.25 | CX LogP: 2.38 | CX LogD: 2.38 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.70 | Np Likeness Score: -0.88 |
References
1. Wang X, Sun C, Fang L, Yin D. (2015) Discovery of novel sphingosine kinase 1 inhibitors via structure-based hierarchical virtual screening, 6 (3): [10.1039/C4MD00312H] |